Abstract

The relationship of positive steroid receptor (SR) status with disease outcome in patients treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil (A-CMF) chemotherapy (CHT) and adjuvant endocrine therapy

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
Marco Colleoni ... Aron Goldhirsch
The Lancet | VOL. 366
Marco Colleoni, et. al.Marco Colleoni ... Aron Goldhirsch
24 Aug 2005
Effect of progestin therapy on steroid receptor status and cellular proliferation in low-grade endometrial adenocarcinoma
Britt Erickson ... Carol Lange
Gynecologic Oncology | VOL. 162
Britt Erickson, et. al.Britt Erickson ... Carol Lange
01 Aug 2021
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Valerie-Jeanne Bardou ... Gary M Clark
Journal of Clinical Oncology | VOL. 21
Valerie-Jeanne Bardou, et. al.Valerie-Jeanne Bardou ... Gary M Clark
15 May 2003
Abstract P5-14-03: Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study
...
Cancer Research | VOL. 83
, et. al. ...
01 Mar 2023
View more papers

More From: European Journal of Cancer Supplements

Paper Title
Journal
Date
Author
Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
Martyn E Caplin
European Journal of Cancer Supplements | VOL. 16
Martyn E CaplinMartyn E Caplin
01 Nov 2021
Editorial board
-
European Journal of Cancer Supplements | VOL. 16
--
01 Nov 2021
Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
Matthew Glover ... Louise Longworth
European Journal of Cancer Supplements | VOL. 16
Matthew Glover, et. al.Matthew Glover ... Louise Longworth
01 Nov 2021
Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
Mohid S Khan ... Marianne E Pavel
European Journal of Cancer Supplements | VOL. 16
Mohid S Khan, et. al.Mohid S Khan ... Marianne E Pavel
01 Nov 2021
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.